United Therapeutics

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

United Therapeutics achieves record 2022 performance, eyes revenue doubling

United Therapeutics had a remarkable year in 2022, with strong financial performance and market acceptance of its products. While facing challenges and questions from analysts, UTHR remains focused on growth and innovation.

United Therapeutics reports robust Q1 growth and eyes new opportunities

United Therapeutics (UTHR) showcased strong revenue growth, product performance, and strategic investments in manufacturing facilities and pipeline trials. Challenges include managing factors affecting Tyvaso revenue and patient flow between key products. However, opportunities from new FDA approvals and organ manufacturing advancements position UTHR for continued growth and innovation.

United Therapeutics achieves record revenue, eyes growth beyond hypertension

United Therapeutics delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and strategic product positioning.
The company's focus on combination therapies, expansion into new markets, and commitment to innovation position it well for future success.
Challenges in market saturation and limited drug options in certain therapeutic areas require targeted strategies and continued R&D efforts for sustained growth.
Overall, United Therapeutics' Q2 performance reflects a balance of strengths, challenges, and opportunities that shape its trajectory in the healthcare sector.

United Therapeutics reports record Q3 revenue and growth opportunities

United Therapeutics had a robust Q3 performance with record revenue and growth, driven by strong performance in the Tyvaso franchise. The company is strategically positioned for growth across its commercial business, pipeline programs, and organ technologies. While facing competition and trial challenges, UTHR remains optimistic about its growth potential and opportunities in addressing critical medical needs.

United Therapeutics reports record revenue growth and highlights innovative pipeline

United Therapeutics (UTHR) delivered a strong performance in Q4 2023, showcasing record revenue growth and confidence in its product portfolio. While facing challenges like patient demand fluctuations and potential competition, UTHR remains focused on innovation and growth opportunities in its pipeline.

United Therapeutics reports record revenue and advances in organ manufacturing

United Therapeutics (UTHR) delivered strong financial performance in Q1 2024, driven by revenue growth and strategic capital allocation initiatives.
The company's focus on product innovation, clinical advancements, and organ manufacturing positions UTHR well for future growth and market competitiveness.
While facing challenges in market penetration and product integration, UTHR has opportunities to expand its market presence, enhance treatment options, and pioneer advancements in organ transplantation.

United Therapeutics (UTHR) reports record revenue and strategic growth

United Therapeutics (UTHR) delivered a strong performance in Q2 2024, driven by record revenue and strategic product focus. The company's emphasis on innovation, market competitiveness, and employee satisfaction positions it well for future growth. Challenges in navigating market dynamics and executing key studies require focused attention, while opportunities exist in expanding market share and optimizing capital allocation.

United Therapeutics reports record revenue growth, faces litigation challenges

United Therapeutics delivered a strong performance in Q3 2024, achieving record revenue and significant growth in key product segments.
While facing challenges such as litigation accrual and slower growth in certain product revenues, the company remains well-positioned for future opportunities.
Investors have shown confidence in United Therapeutics, as reflected in the stock appreciation post ASR program, indicating positive market sentiment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Corcept Therapeutics

Catalyst Pharmaceuticals

Exelixis

Ligand Pharmaceuticals

The top five biotech stocks today have several commonalities. Among them are strong ratings.

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)---- $UTHR #biotech--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world's first transplant of a UKidney, which it produced, into a living person on November 25, 2024. The transplant is the fourth xenotransplant using United Therapeutics' xeno organs into living humans, following two successful UHeart transplants at the University of Maryland Medicine in 2022 and 2023 and a successful UThymoKidney.

United Therapeutics Announces Successful World's First UKidney Transplant

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report?

UTHR's competitive advantages, including high returns on capital and successfully recycling of profits, support a bullish outlook. United Therapeutics' Q3 FY '24 earnings showed strong growth across major product lines, with Tyvaso, Orenitram, and Unituxin all posting significant YoY increases. My numbers project a 40% growth in earnings power for the business over the coming 2-3 years.

United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy

Despite legal challenges and exclusivity risks, United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. UTHR is innovating in organ transplantation and bioengineered organs, including xenotransplantation and ex vivo lung perfusion, which could revolutionize the market. Legal battles, particularly with Liquidia, threaten United Therapeutics' intellectual property, affecting its Tyvaso franchise and competitive position in PAH.

United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom

United Therapeutics Corporation's stock has surged over 300% since my 2020 “Buy” rating, driven by strong sales of Tyvaso DPI and other PAH treatments. Despite facing generic competition, United has maintained resilience, leveraging strategic litigation and innovative product development to protect and grow its revenue streams. United's future growth hinges on expanding Tyvaso DPI's market and advancing its pipeline, including promising IPF treatments and groundbreaking organ transplant technologies.

United Therapeutics: One To Believe In Despite Competitive Threats

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company's operations during a fireside chat session at the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. The session will take place on Tuesday, November 12, 2024, from 2:45 p.m. to 3:20 p.m., Pacific Standard.

United Therapeutics Corporation to Present at the UBS Global Healthcare Conference

United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy?

United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?

UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.

United Therapeutics Q3 Earnings & Sales Beat Estimates

United Therapeutics Corporation (NASDAQ:UTHR ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Executive Vice President-Product Development & Xenotransplantation Conference Call Participants Joseph Thome - TD Cowen Roanna Ruiz - Leerink Partners Andreas Argyrides - Oppenheimer Roger Song - Jefferies Jessica Fye - JPMorgan Ash Verma - UBS Operator Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2024 Earnings Webcast. My name is Dave, and I will be your conference operator today.

United Therapeutics Corporation (UTHR) Q3 2024 Earnings Call Transcript

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings

United Therapeutics (UTHR) came out with quarterly earnings of $6.39 per share, beating the Zacks Consensus Estimate of $6.18 per share. This compares to earnings of $5.38 per share a year ago.

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023. "I'm proud of the close to 1,300 Unitherians who have contributed to yet another record revenue quarter and reaching a $3.

United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

Beyond analysts' top -and-bottom-line estimates for United Therapeutics (UTHR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.

Curious about United Therapeutics (UTHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics

SILVER SPRING, Md. & JACKSONVILLE, Fla.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and its subsidiary Lung Bioengineering Inc. (LBE) announced that the 500th lung transplant utilizing LBE's centralized ex vivo lung perfusion (EVLP) service was completed last month. These 500 transplants were the result of evaluating over 800 donated lungs using centralized EVLP since 2014. The 500th transplant was completed in Jacksonville at Mayo Clinic in F.

United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 30, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via.

United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024

This biotech stock hit a buy point and a new high. The company's sales and earnings continue to grow with earnings out soon.

Profitable Biotech In Buy Zone As Earnings Approach

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented at the CHEST 2024 Annual Meeting hosted by the American College of Chest Physicians taking place October 6-9, 2024, in Boston. United Therapeutics will sponsor the Tyvaso DPI®: Clinical Pearls and Drug-Device Characteristics Symposi.

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its 2024 Corporate Responsibility and Public Benefit Report (Report) covering its FY 2023 progress toward its public benefit goals and objectives and summarizing its efforts to advance the interests of patients and other stakeholders. “Our 2023 financial performance helps set us up for the next revolutionary wave o.

United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever

United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue?

Revenue growth and a recent regulatory win are driving shares of United Therapeutics Corporation (UTHR) upward.

United Therapeutics Shares Thrive

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will present overviews and updates on the company's operations during fireside chat sessions at two upcoming investor conferences. Michael Benkowitz, President and Chief Operating Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Wednesday, September 4, 2024.

United Therapeutics Corporation to Present at Upcoming Investor Conferences

United Therapeutics Corporation remains a buy with strong growth potential and high returns on invested capital. Q2 FY'24 earnings show continued growth in sales and earnings, with upsides in its Tyvaso segment. The company has started share buybacks and is on track to reach a $3 billion revenue run rate by FY'25, supporting a valuation of $400/share.

News for United Therapeutics Stock (UTHR)